Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session and the average volume of the stock remained 2.24million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.70%.

Omeros Corporation (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764.Omeros Corporation (NASDAQ:OMER) rose 8.92 percent to $17.47 Wednesday on volume of 1.15million shares. The intra-day range of the stock was $16.20 to $17.72. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $592.45million.

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of the company’s stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, for a total transaction of $127,200.00. Following the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. Insys Therapeutics Inc (NASDAQ:INSY)’s stock on June 25, 2014 reported a increase of 6.51% to the closing price of $30.90. Its fifty two weeks range is $7.78 -$57.91. The total market capitalization recorded $1.06billion. The overall volume in the last trading session was 805,607.00million shares. In its share capital, INSY has 34.23million outstanding shares.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Director John Maraganore bought $101,154 worth of company, buying 2,300 shares at a cost of $43.98 each. Before this latest buy, Maraganore bought AGIO at 2 other times during the past twelve months, for a total cost of $248,994 at an average of $23.53 per share. On Wednesday, shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped -0.09% to close the day at $43.84. Company return on investment (ROI) is -30.00% and its monthly performance is recorded as 21.31%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly revenue growth is 20.97%.

BioTime Inc (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $2.50 per share, with a total value of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) stock performance was 3.57% in last session and finished the day at $3.19. Traded volume was 204,151.00million shares in the last session and the average volume of the stock remained 264.96K shares. The beta of the stock remained 1.30. BioTime, Inc. (NYSEMKT:BTX) insider ownership is 9.40%.